leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...120121122123124125126127128129130...235236»
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Clinical, Journal, Tumor Mutational Burden, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker:  A Case of a Pathological Complete Response to Neoadjuvant Nivolumab Plus Ipilimumab in Periampullary Adenocarcinoma. (Pubmed Central) -  Sep 30, 2021   
    Comprehensive genomic profiling is beneficial in periampullary adenocarcinomas as it can identify tumors with specific genetic characteristics, like MSI-high, dMMR or high TMB that respond well to immune checkpoint inhibitors. When these characteristics are present and the goal of treatment is to facilitate downstage and prolong progression free survival, nivolumab plus ipilimumab should be considered, but trials in periampullary adenocarcinomas are required to confirm usage.
  • ||||||||||  5-fluorouracil / Generic mfg., irinotecan / Generic mfg.
    Review, Journal:  Recent Updates on Mechanisms of Resistance to 5-Fluorouracil and Reversal Strategies in Colon Cancer Treatment. (Pubmed Central) -  Sep 29, 2021   
    Indeed, the successful modulation of these mechanisms have been the game plan of numerous studies that had employed small molecule inhibitors, plant-based small molecules, and non-coding RNA regulators to effectively reverse 5-FU resistance in colon cancer cells. It is hoped that these studies would provide fundamental knowledge to further our understanding prior developing novel drugs in the near future that would synergistically work with 5-FU to potentiate its antitumor effects and improve the patient's overall survival.
  • ||||||||||  irinotecan / Generic mfg.
    Review, Journal:  A Perspective on the Role of Microbiome for Colorectal Cancer Treatment. (Pubmed Central) -  Sep 29, 2021   
    Several other studies have also proposed manipulation of the microbiota to optimise CRC treatment. In this review, we summarise the current advancement of knowledge on how microbiota and CRC treatments interact with each other and how this interaction may shed some light on the development of personalised microbiota manipulations that improve CRC treatment outcomes.
  • ||||||||||  Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
    Clinical, Review, Journal:  Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer. (Pubmed Central) -  Sep 29, 2021   
    We considered design, endpoints, inclusion criteria and results of available randomized trials. Neoadjuvant treatment appears to be at least a feasible strategy for patients with resectable pancreatic cancer.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial completion date, Trial primary completion date, Metastases:  Conversion From Unresectable To Resectable Metastatic Colorectal Cancer. (clinicaltrials.gov) -  Sep 29, 2021   
    P2,  N=32, Not yet recruiting, 
    Active, not recruiting --> Completed Trial completion date: Aug 2024 --> Mar 2026 | Trial primary completion date: Aug 2022 --> Mar 2024
  • ||||||||||  EndoTAG-1 (paclitaxel liposomal) / Sinphar Pharma
    Trial completion date, Trial primary completion date, Metastases:  EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX (clinicaltrials.gov) -  Sep 29, 2021   
    P3,  N=218, Active, not recruiting, 
    Trial completion date: Aug 2024 --> Mar 2026 | Trial primary completion date: Aug 2022 --> Mar 2024 Trial completion date: Jun 2022 --> Jan 2023 | Trial primary completion date: Jul 2021 --> Nov 2021
  • ||||||||||  Clinical, Review, Journal:  Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatin. (Pubmed Central) -  Sep 29, 2021   
    Trial completion date: Jun 2022 --> Jan 2023 | Trial primary completion date: Jul 2021 --> Nov 2021 The failure of PRODIGE 7 to improve survival with surgery plus HIPEC following NACT may reflect diminished oxaliplatin cytotoxicity in patients whose residual disease has been selected for oxaliplatin and 5-FU resistance.
  • ||||||||||  Trial completion date, Trial primary completion date, Metastases:  SMART: Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer (clinicaltrials.gov) -  Sep 29, 2021   
    P=N/A,  N=27, Not yet recruiting, 
    GnP after FOLFIRINOX is expected to be one of the second-line recommendations for patients with unresectable pancreatic cancer. Trial completion date: Sep 2025 --> Mar 2026 | Trial primary completion date: Sep 2023 --> Mar 2024
  • ||||||||||  Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
    Trial completion:  Post Marketing Surveillance Study for ONIVYDE (clinicaltrials.gov) -  Sep 28, 2021   
    P=N/A,  N=94, Completed, 
    This consensus aimed to drive the application of cmFOLFOXIRI in the field of colorectal cancer in order to bring benefits to colorectal cancer patients. Recruiting --> Completed
  • ||||||||||  Trial primary completion date:  Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial (clinicaltrials.gov) -  Sep 26, 2021   
    P2,  N=125, Recruiting, 
    Trial primary completion date: May 2021 --> May 2022 Trial primary completion date: Aug 2022 --> Aug 2023
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Clinical, Review, Journal:  Interventions and Outcomes for Neoadjuvant Treatment of T4 Colon Cancer: A Scoping Review. (Pubmed Central) -  Sep 26, 2021   
    Future studies should prioritize evaluating clear selection criteria and rationale for specific neoadjuvant strategies. Validation of outcomes in multi-center, randomized trials for XELOX and FOLFOX have the most to contribute to the growing evidence for this poorly managed disease.
  • ||||||||||  irinotecan / Generic mfg.
    Clinical, Review, Journal:  Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma. (Pubmed Central) -  Sep 24, 2021   
    There is therefore considerable interest in neoadjuvant treatment strategies for patients with resectable and borderline resectable pancreatic cancer as a way to provide early systemic treatment of micrometastatic disease, facilitate lymph node downstaging, and increase the likelihood of negative resection margins (R0). This review will focus on key aspects of completed trials evaluating adjuvant therapy in resectable pancreatic cancer and will provide an overview of emerging evidence supporting the use of neoadjuvant treatment strategies for both resectable and borderline resectable pancreatic cancer.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Clinical, Review, Journal:  Neoadjuvant treatment for rectal cancer (Pubmed Central) -  Sep 24, 2021   
    These therapeutic strategies have not yet been validated but should be in the news tomorrow. The purpose of this review is to present recent data reported in patients with locally advanced rectal cancer.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly
    Trial initiation date, Metastases:  Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy (clinicaltrials.gov) -  Sep 24, 2021   
    P=N/A,  N=51, Not yet recruiting, 
    The purpose of this review is to present recent data reported in patients with locally advanced rectal cancer. Initiation date: Jun 2021 --> Oct 2021
  • ||||||||||  methotrexate / Generic mfg.
    Clinical, Review, Journal:  Immunoglobulin D-kappa multiple myeloma in a patient with rheumatoid arthritis: A case report and review of the literature. (Pubmed Central) -  Sep 22, 2021   
    A 77-year-old Japanese woman with a 21-year history of seropositive, erosive rheumatoid arthritis (RA) and a 10-year history of methotrexate (MTX) therapy was admitted with malaise and mild consciousness disturbance...As we first assumed drug-induced toxicity by MTX and eldecalcitol, both were discontinued and leucovorin rescue therapy and calcitonin were administered...Although IgD MM is characterized by its clinical severity and poor prognosis compared to other subtypes, it is often misdiagnosed or mistaken as light chain type MM, as in the present case, because of the low level of IgD M-protein, resulting in delayed diagnosis. Physicians must take MM into consideration as a differential diagnosis when inactive RA patients present with inexplicable elevated calcium, renal failure, anemia, and bone lesion symptoms and should be aware of IgD MM to establish the correct diagnosis promptly.
  • ||||||||||  methotrexate / Generic mfg.
    Journal:  Poisoning related to therapeutic error in prolonged low-dose methotrexate treatment. (Pubmed Central) -  Sep 22, 2021   
    In our experience, the age, the total taken dose and the number of days of assumption are predictive for the presence/absence of clinical manifestations. These parameters must be evaluated together in order to identify patients needing a maximal starting treatment with folinic acid and a closer monitoring.
  • ||||||||||  irinotecan / Generic mfg.
    Journal, BRCA Biomarker, PARP Biomarker, IO biomarker:  Diagnostics and therapy of pancreatic carcinoma (Pubmed Central) -  Sep 22, 2021   
    Targeted therapies and immune checkpoint inhibitors could not be established. In patients with a proven germline mutation in the BRCA gene, a therapy with the PARP inhibitor olaparib is in the approval process.This article provides an overview of differential diagnoses, meaningful diagnostics, therapeutic concepts to improve surgical treatment, possibilities of palliative chemotherapy and targeted therapy in the presence of a BRCA mutation.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Journal:  CHEMOTHERAPY IN RECTAL CANCER. (Pubmed Central) -  Sep 21, 2021   
    The obtained data for patients with stage III RC showed that at all studied time intervals, the highest percentage of surviving patients was recorded in those who received chemotherapeutic treatment according to the FOLFOX regimen. In patients with stage II RC, the most ef f ective was Mejo regimen - 30.7% (survived patients for the 5 year observation).